We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Logos Biosystems

Logos Biosystems is the life science solutions of Aligned Genetics, Inc., dedicated to the development and commercial... read more Featured Products: More products

Download Mobile App




Automated Fluorescent Microbial Cell Counter Detects Urinary Tract Infection

By LabMedica International staff writers
Posted on 15 Jul 2020
Urinary tract infections (UTI) accounted for around 400,000 hospitalizations, resulting in an estimated cost burden of approximately USD 2.8 billion in the USA. More...
Between 50% and 60% of adult women will have at least one UTI in their life, and close to 10% of postmenopausal women indicate that they had a UTI in the previous year.

A rapid urinalysis is usually conducted upon presentation with UTI‐related symptoms in patients. A rapid urinalysis screens the urine for ketones, proteins, reducing substances, red blood cells (RBC), white blood cells (WBC), nitrites, and pH levels outside the normal range (4.5 to 8.0). The most common pathogen associated with UTI globally is Escherichia coli.

Gastroenterologists and their associates at the Sinai Hospital (Baltimore, MD, USA) obtained clean‐catch urine samples from 10 healthy control subjects with a negative urinalysis result and 11 subjects with suspected UTI with a positive urinalysis and culture result for E. coli. Urine samples that received a positive result were plated onto blood agar and MacConkey medium for growth analysis. Urine samples were analyzed using the QUANTOM Tx Microbial Cell Counter (Logos Biosystems, Annandale, VA, USA) upon reception from the microbiology laboratory.

The scientists reported that the mean cellular concentration for the 11 E. coli‐positive samples was 1.01 × 108 cells/mL (range = 2.5 × 107–3.29 × 108 ± SD = 8.9 × 107). The average cellular concentration for the 10 control samples was 2.35 × 106 cells/mL (range = 9.42 × 105–5.93 × 106 ± SD = 1.56 × 106). The difference in cellular concentration between the E. coli‐positive and control groups was found to be statistically significant.

The authors concluded that the automated microbial cell counter represents a significant step toward high throughput, reproducible microbial cell observation, and quantification. A significant difference in cellular concentration was observed between E. coli‐positive UTI samples and controls measured with an automated microbial cell counter. Thus, automated microbial cell counters may serve important roles as preliminary screening tools in clinical diagnostic settings. The study was published on July 4, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sinai Hospital
Logos Biosystems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.